Keywords
Abstract
Maqola dislipidemiya va yurak kasalliklari: zamonaviy yondashuvlar va dorilar samaradorligi mavzusini o‘rganishga bag‘ishlangan. Dislipidemiya — qon lipidlarining, xususan, xolesterin va triglitseridlar miqdorining normal chegaralardan oshishi yoki kamayishi bilan xarakterlanadigan holat bo‘lib, u yurak-qon tomir kasalliklari rivojlanishida asosiy xavf omillaridan biridir. Ishda zamonaviy davolash strategiyalari, shu jumladan statinlar, fibratlar, ezetimib va boshqa lipidni tartibga soluvchi preparatlar samaradorligi tahlil qilingan. Shuningdek, bemorlarning hayot tarzi, parhez va jismoniy faollik dislipidemiya bilan bog‘liq yurak kasalliklarining oldini olishda muhim omillar sifatida ko‘rib chiqiladi.
References
1. Grundy S. M., Stone N. J., Bailey A. L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation, 2019;139:e1082–e1143.
2. Cannon C. P., Blazing M. A., Giugliano R. P., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015;372:2387–2397.
3. Stone N. J., Robinson J. G., Lichtenstein A. H., et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation, 2014;129:S1–S45.
4. Catapano A. L., Reiner Ž., De Backer G., et al. ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016;37:2999–3058.
5. Davidson M. H., Stein E. A., Bays H., et al. Safety and Efficacy of Fibrates in Dyslipidemia Management. Am J Cardiol, 2007;99:410–419.
6. World Health Organization (WHO). Cardiovascular Diseases and Dyslipidemia: Fact Sheet. Geneva, 2022.